[L02BA01, tamoxifen, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tamoxifen.]
[B01AE07, dabigatran etexilate, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dabigatran etexilate.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Tetracaine.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Enfortumab vedotin.]
[J01FA08, troleandomycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Troleandomycin.]
[L01EX04, vandetanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Telaprevir.]
[B01AF01, rivaroxaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Enfortumab vedotin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Enfortumab vedotin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Enfortumab vedotin.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Enfortumab vedotin.]
[J05AE02, indinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin.]
[L01ED01, crizotinib, The metabolism of Enfortumab vedotin can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Enfortumab vedotin can be decreased when combined with Ziprasidone.]
[J02AC03, voriconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Voriconazole.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Enfortumab vedotin.]
[R07AX02, ivacaftor, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ivacaftor.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Enfortumab vedotin.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Enfortumab vedotin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Enfortumab vedotin.]
[G04BD12, mirabegron, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Enfortumab vedotin.]
[L01EX05, regorafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Regorafenib.]
[J05AE04, nelfinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Enfortumab vedotin.]
[G04BE03, sildenafil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lomitapide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Enfortumab vedotin.]
[A10BK02, canagliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.]
[A06AX06, tegaserod, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzocaine.]
[L04AA18, everolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Riociguat.]
[J05AP05, simeprevir, The metabolism of Enfortumab vedotin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sofosbuvir.]
[A16AA07, metreleptin, The metabolism of Enfortumab vedotin can be increased when combined with Metreleptin.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Enfortumab vedotin.]
[B01AC26, vorapaxar, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Idelalisib.]
[N05CM19, suvorexant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Eliglustat.]
[L01EX09, nintedanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nintedanib.]
[J05AP09, dasabuvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dasabuvir.]
[B01AF03, edoxaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Edoxaban.]
[L01EF01, palbociclib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Enfortumab vedotin.]
[J05AP07, daclatasvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Daclatasvir.]
[J05AP06, asunaprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Asunaprevir.]
[A04AD14, rolapitant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Flibanserin.]
[J02AC05, isavuconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Enfortumab vedotin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Enfortumab vedotin.]
[B01AC27, selexipag, The serum concentration of Enfortumab vedotin can be increased when it is combined with Selexipag.]
[J05AP10, elbasvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Grazoprevir.]
[L01XX52, venetoclax, The metabolism of Enfortumab vedotin can be decreased when combined with Venetoclax.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Bupivacaine.]
[L01XX27, arsenic trioxide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Arsenic trioxide.]
[L01EF02, ribociclib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ribociclib.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Oxybuprocaine.]
[J05AE09, tipranavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tipranavir.]
[L01EX10, midostaurin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Midostaurin.]
[B01AF04, betrixaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Betrixaban.]
[L01XX59, enasidenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enfortumab vedotin.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Enfortumab vedotin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Enfortumab vedotin.]
[C07AB07, bisoprolol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Enfortumab vedotin can be increased when it is combined with Efavirenz.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ertugliflozin.]
[L02BB05, apalutamide, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Enfortumab vedotin can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Carvedilol.]
[B02BX08, avatrombopag, The serum concentration of Enfortumab vedotin can be increased when it is combined with Avatrombopag.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Enfortumab vedotin.]
[H01CC03, elagolix, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Enfortumab vedotin can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Enfortumab vedotin.]
[L01EM04, duvelisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Omadacycline.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Chloroprocaine.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Enfortumab vedotin.]
[R03BB08, revefenacin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Revefenacin.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Enfortumab vedotin.]
[L01EX13, gilteritinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib.]
[J01FA09, clarithromycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clobazam.]
[L02BB06, darolutamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Darolutamide.]
[L01EJ02, fedratinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Istradefylline.]
[J01XX09, daptomycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Daptomycin.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Enfortumab vedotin.]
[N02CC08, lasmiditan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Enfortumab vedotin.]
[S01AA13, fusidic acid, The metabolism of Enfortumab vedotin can be decreased when combined with Fusidic acid.]
[N05CM21, lemborexant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tazemetostat.]
[N02CD06, rimegepant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rimegepant.]
[J05AE05, amprenavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Selumetinib.]
[C01BD07, dronedarone, The metabolism of Enfortumab vedotin can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Enfortumab vedotin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Capmatinib.]
[L01EX19, ripretinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ripretinib.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Dyclonine.]
[J05AX29, fostemsavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin.]
[L04AC19, satralizumab, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pralsetinib.]
[B06AC06, berotralstat, The metabolism of Enfortumab vedotin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Enfortumab vedotin can be increased when it is combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Enfortumab vedotin.]
[L01EK03, tivozanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Enfortumab vedotin.]
[L01XX73, sotorasib, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Enfortumab vedotin can be decreased when combined with Ciprofloxacin.]
[L04AA48, belumosudil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Belumosudil.]
[N06AX25, St. John's wort extract, The metabolism of Enfortumab vedotin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clomifene.]
[C01EB24, mavacamten, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Mavacamten.]
[N05AH02, clozapine, The metabolism of Enfortumab vedotin can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Enfortumab vedotin.]
[A10BK06, sotagliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Enfortumab vedotin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cocaine.]
[M04AC01, colchicine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Colchicine.]
[J01FA15, telithromycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Telithromycin.]
[J02AC02, itraconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Itraconazole.]
[J02AC04, posaconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enfortumab vedotin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tenofovir disoproxil.]
[S01XA18, cyclosporine, The metabolism of Enfortumab vedotin can be decreased when combined with Cyclosporine.]
[C03XA02, conivaptan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vardenafil.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Enfortumab vedotin.]
[G03XA01, danazol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Danazol.]
[N06AX06, nefazodone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nefazodone.]
[S03BA01, dexamethasone, The metabolism of Enfortumab vedotin can be increased when combined with Dexamethasone.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cinchocaine.]
[L01DC04, ixabepilone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ixabepilone.]
[C08CA03, isradipine, The metabolism of Enfortumab vedotin can be decreased when combined with Isradipine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Enfortumab vedotin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Enfortumab vedotin.]
[J05AE08, atazanavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Enfortumab vedotin can be decreased when combined with Diltiazem.]
[C05CA03, diosmin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Diphenhydramine.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Enfortumab vedotin.]
[S02AA12, rifamycin SV, The metabolism of Enfortumab vedotin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Enfortumab vedotin can be increased when combined with Rifapentine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ropivacaine.]
[A04AD12, aprepitant, The metabolism of Enfortumab vedotin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Enfortumab vedotin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Enfortumab vedotin.]
[C02KX02, ambrisentan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ranolazine.]
[C10AA01, simvastatin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Simvastatin.]
[G01AF05, econazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Econazole.]
[C07AB13, talinolol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Talinolol.]
[L02BA02, toremifene, The serum concentration of Enfortumab vedotin can be increased when it is combined with Toremifene.]
[C08CA12, mepirodipine, The metabolism of Enfortumab vedotin can be decreased when combined with Barnidipine.]
[N03AX15, zonisamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Zonisamide.]
[N02CA02, ergotamine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Enfortumab vedotin can be decreased when combined with Erythromycin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Enfortumab vedotin.]
[L04AD02, tacrolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tacrolimus.]
[R06AX12, terfenadine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Enfortumab vedotin can be decreased when combined with Fluvoxamine.]
[C10AA03, pravastatin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pravastatin.]
[J02AC01, fluconazole, The metabolism of Enfortumab vedotin can be decreased when combined with Fluconazole.]
[J05AE10, darunavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Darunavir.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Enfortumab vedotin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Enfortumab vedotin.]
[L01EH01, lapatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lapatinib.]
[L01EX02, sorafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sorafenib.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin.]
[C08CA10, nilvadipine, The metabolism of Enfortumab vedotin can be decreased when combined with Nilvadipine.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Enfortumab vedotin.]
[N06AX17, milnacipran, The metabolism of Enfortumab vedotin can be decreased when combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sitagliptin.]
[J04AC01, isoniazid, The metabolism of Enfortumab vedotin can be decreased when combined with Isoniazid.]
[J02AB02, ketoconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Levoketoconazole.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Lidocaine.]
[A07DA03, loperamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Enfortumab vedotin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mannitol.]
[P01BC02, mefloquine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mefloquine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Mepivacaine.]
[N05AX13, paliperidone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone.]
[H03BB02, methimazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Methimazole.]
[V04CG05, methylene blue, The serum concentration of Enfortumab vedotin can be increased when it is combined with Methylene blue.]
[S02AA13, miconazole, The metabolism of Enfortumab vedotin can be decreased when combined with Miconazole.]
[G03XB01, mifepristone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Enfortumab vedotin can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Amiodarone.]
[N02AA01, morphine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Morphine.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Enfortumab vedotin.]
[G04CA04, silodosin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Silodosin.]
[N03AB05, fosphenytoin, The metabolism of Enfortumab vedotin can be increased when combined with Fosphenytoin.]
[V03AB15, naloxone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Naloxone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enfortumab vedotin.]
[N06AX23, desvenlafaxine, The metabolism of Enfortumab vedotin can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Enfortumab vedotin can be decreased when combined with Nicardipine.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Enfortumab vedotin.]
[A16AX07, sapropterin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sapropterin.]
[N05CA01, pentobarbital, The metabolism of Enfortumab vedotin can be increased when combined with Pentobarbital.]
[N03AA02, phenobarbital, The metabolism of Enfortumab vedotin can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Enfortumab vedotin can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mibefradil.]
[J05AE01, saquinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Saquinavir.]
[J05AG02, delavirdine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Delavirdine.]
[J05AE03, ritonavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ritonavir.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Enfortumab vedotin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Enfortumab vedotin can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Procaine.]
[C01BC03, propafenone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Enfortumab vedotin.]
[C01BA01, quinidine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinine.]
[C02AA02, reserpine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Enfortumab vedotin can be increased when combined with Rifampicin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Enfortumab vedotin.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Enfortumab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi.]
[L02BA01, tamoxifen, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tamoxifen.]
[B01AE07, dabigatran etexilate, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dabigatran etexilate.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Tetracaine.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Enfortumab vedotin.]
[J01FA08, troleandomycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Troleandomycin.]
[L01EX04, vandetanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Telaprevir.]
[B01AF01, rivaroxaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Enfortumab vedotin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Enfortumab vedotin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Enfortumab vedotin.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Enfortumab vedotin.]
[J05AE02, indinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin.]
[L01ED01, crizotinib, The metabolism of Enfortumab vedotin can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Enfortumab vedotin can be decreased when combined with Ziprasidone.]
[J02AC03, voriconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Voriconazole.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Enfortumab vedotin.]
[R07AX02, ivacaftor, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ivacaftor.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Enfortumab vedotin.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Enfortumab vedotin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Enfortumab vedotin.]
[G04BD12, mirabegron, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Enfortumab vedotin.]
[L01EX05, regorafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Regorafenib.]
[J05AE04, nelfinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Enfortumab vedotin.]
[G04BE03, sildenafil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lomitapide.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Enfortumab vedotin.]
[A10BK02, canagliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.]
[A06AX06, tegaserod, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzocaine.]
[L04AA18, everolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Riociguat.]
[J05AP05, simeprevir, The metabolism of Enfortumab vedotin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sofosbuvir.]
[A16AA07, metreleptin, The metabolism of Enfortumab vedotin can be increased when combined with Metreleptin.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Enfortumab vedotin.]
[B01AC26, vorapaxar, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vorapaxar.]
[L01XH04, belinostat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Idelalisib.]
[N05CM19, suvorexant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Eliglustat.]
[L01EX09, nintedanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nintedanib.]
[J05AP09, dasabuvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dasabuvir.]
[B01AF03, edoxaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Edoxaban.]
[L01EF01, palbociclib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Enfortumab vedotin.]
[J05AP07, daclatasvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Daclatasvir.]
[J05AP06, asunaprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Asunaprevir.]
[A04AD14, rolapitant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Flibanserin.]
[J02AC05, isavuconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Enfortumab vedotin.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Enfortumab vedotin.]
[B01AC27, selexipag, The serum concentration of Enfortumab vedotin can be increased when it is combined with Selexipag.]
[J05AP10, elbasvir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Grazoprevir.]
[L01XX52, venetoclax, The metabolism of Enfortumab vedotin can be decreased when combined with Venetoclax.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Bupivacaine.]
[L01XX27, arsenic trioxide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Arsenic trioxide.]
[L01EF02, ribociclib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ribociclib.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Oxybuprocaine.]
[J05AE09, tipranavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tipranavir.]
[L01EX10, midostaurin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Midostaurin.]
[B01AF04, betrixaban, The serum concentration of Enfortumab vedotin can be increased when it is combined with Betrixaban.]
[L01XX59, enasidenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enfortumab vedotin.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Enfortumab vedotin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Enfortumab vedotin.]
[C07AB07, bisoprolol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Enfortumab vedotin can be increased when it is combined with Efavirenz.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ertugliflozin.]
[L02BB05, apalutamide, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Enfortumab vedotin can be increased when combined with Carbamazepine.]
[C07AG02, carvedilol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Carvedilol.]
[B02BX08, avatrombopag, The serum concentration of Enfortumab vedotin can be increased when it is combined with Avatrombopag.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Enfortumab vedotin.]
[H01CC03, elagolix, The serum concentration of Enfortumab vedotin can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Enfortumab vedotin can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Enfortumab vedotin.]
[L01EM04, duvelisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Omadacycline.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Chloroprocaine.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Enfortumab vedotin.]
[R03BB08, revefenacin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Revefenacin.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Enfortumab vedotin.]
[L01EX13, gilteritinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib.]
[J01FA09, clarithromycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clobazam.]
[L02BB06, darolutamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Darolutamide.]
[L01EJ02, fedratinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Enfortumab vedotin can be increased when it is combined with Istradefylline.]
[J01XX09, daptomycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Daptomycin.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Enfortumab vedotin.]
[N02CC08, lasmiditan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lasmiditan.]
[N03AX25, cenobamate, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Enfortumab vedotin.]
[S01AA13, fusidic acid, The metabolism of Enfortumab vedotin can be decreased when combined with Fusidic acid.]
[N02CD06, rimegepant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Rimegepant.]
[J05AE05, amprenavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Selumetinib.]
[C01BD07, dronedarone, The metabolism of Enfortumab vedotin can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Enfortumab vedotin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Capmatinib.]
[L01EX19, ripretinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ripretinib.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Dyclonine.]
[J05AX29, fostemsavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin.]
[L04AC19, satralizumab, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Satralizumab.]
[L01EX23, pralsetinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pralsetinib.]
[B06AC06, berotralstat, The metabolism of Enfortumab vedotin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Enfortumab vedotin can be increased when it is combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Enfortumab vedotin.]
[L01EK03, tivozanib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Enfortumab vedotin.]
[L01XX73, sotorasib, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Enfortumab vedotin can be decreased when combined with Ciprofloxacin.]
[L04AA48, belumosudil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Belumosudil.]
[N06AX25, St. John's wort extract, The metabolism of Enfortumab vedotin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Maribavir.]
[D11AH08, abrocitinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clofazimine.]
[B06AX04, mitapivat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Enfortumab vedotin can be increased when it is combined with Clomifene.]
[C01EB24, mavacamten, The serum concentration of Enfortumab vedotin can be decreased when it is combined with Mavacamten.]
[N05AH02, clozapine, The metabolism of Enfortumab vedotin can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Enfortumab vedotin.]
[A10BK06, sotagliflozin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Enfortumab vedotin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cocaine.]
[M04AC01, colchicine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Colchicine.]
[J01FA15, telithromycin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Telithromycin.]
[J02AC02, itraconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Itraconazole.]
[J02AC04, posaconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enfortumab vedotin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tenofovir disoproxil.]
[S01XA18, cyclosporine, The metabolism of Enfortumab vedotin can be decreased when combined with Cyclosporine.]
[C03XA02, conivaptan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Vardenafil.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Enfortumab vedotin.]
[G03XA01, danazol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Danazol.]
[N06AX06, nefazodone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nefazodone.]
[S03BA01, dexamethasone, The metabolism of Enfortumab vedotin can be increased when combined with Dexamethasone.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cinchocaine.]
[L01DC04, ixabepilone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ixabepilone.]
[C08CA03, isradipine, The metabolism of Enfortumab vedotin can be decreased when combined with Isradipine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Enfortumab vedotin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Enfortumab vedotin.]
[J05AE08, atazanavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Enfortumab vedotin can be decreased when combined with Diltiazem.]
[C05CA03, diosmin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Diphenhydramine.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Enfortumab vedotin.]
[S02AA12, rifamycin SV, The metabolism of Enfortumab vedotin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Enfortumab vedotin can be increased when combined with Rifapentine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ropivacaine.]
[A04AD12, aprepitant, The metabolism of Enfortumab vedotin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Enfortumab vedotin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Enfortumab vedotin.]
[C02KX02, ambrisentan, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ranolazine.]
[C10AA01, simvastatin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Simvastatin.]
[G01AF05, econazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Econazole.]
[C07AB13, talinolol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Talinolol.]
[L02BA02, toremifene, The serum concentration of Enfortumab vedotin can be increased when it is combined with Toremifene.]
[C08CA12, mepirodipine, The metabolism of Enfortumab vedotin can be decreased when combined with Barnidipine.]
[N03AX15, zonisamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Zonisamide.]
[N02CA02, ergotamine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Enfortumab vedotin can be decreased when combined with Erythromycin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Enfortumab vedotin.]
[L04AD02, tacrolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tacrolimus.]
[R06AX12, terfenadine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Enfortumab vedotin can be decreased when combined with Fluvoxamine.]
[C10AA03, pravastatin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Pravastatin.]
[J02AC01, fluconazole, The metabolism of Enfortumab vedotin can be decreased when combined with Fluconazole.]
[J05AE10, darunavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Darunavir.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Enfortumab vedotin.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Enfortumab vedotin.]
[L01EH01, lapatinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lapatinib.]
[L01EX02, sorafenib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sorafenib.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin.]
[C08CA10, nilvadipine, The metabolism of Enfortumab vedotin can be decreased when combined with Nilvadipine.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Enfortumab vedotin.]
[N06AX17, milnacipran, The metabolism of Enfortumab vedotin can be decreased when combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sitagliptin.]
[J04AC01, isoniazid, The metabolism of Enfortumab vedotin can be decreased when combined with Isoniazid.]
[J02AB02, ketoconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Levoketoconazole.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Lidocaine.]
[A07DA03, loperamide, The serum concentration of Enfortumab vedotin can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Enfortumab vedotin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Enfortumab vedotin can be increased when it is combined with Temsirolimus.]
[L01EA03, nilotinib, The serum concentration of Enfortumab vedotin can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mannitol.]
[P01BC02, mefloquine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mefloquine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Mepivacaine.]
[N05AX13, paliperidone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone.]
[H03BB02, methimazole, The serum concentration of Enfortumab vedotin can be increased when it is combined with Methimazole.]
[V04CG05, methylene blue, The serum concentration of Enfortumab vedotin can be increased when it is combined with Methylene blue.]
[S02AA13, miconazole, The metabolism of Enfortumab vedotin can be decreased when combined with Miconazole.]
[G03XB01, mifepristone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Enfortumab vedotin can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Amiodarone.]
[N02AA01, morphine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Morphine.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Enfortumab vedotin.]
[G04CA04, silodosin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Silodosin.]
[N03AB05, fosphenytoin, The metabolism of Enfortumab vedotin can be increased when combined with Fosphenytoin.]
[V03AB15, naloxone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Naloxone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enfortumab vedotin.]
[N06AX23, desvenlafaxine, The metabolism of Enfortumab vedotin can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Enfortumab vedotin can be decreased when combined with Nicardipine.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Enfortumab vedotin.]
[A16AX07, sapropterin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Sapropterin.]
[N05CA01, pentobarbital, The metabolism of Enfortumab vedotin can be increased when combined with Pentobarbital.]
[N03AA02, phenobarbital, The metabolism of Enfortumab vedotin can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Enfortumab vedotin can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, The serum concentration of Enfortumab vedotin can be increased when it is combined with Mibefradil.]
[J05AE01, saquinavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Saquinavir.]
[J05AG02, delavirdine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Delavirdine.]
[J05AE03, ritonavir, The serum concentration of Enfortumab vedotin can be increased when it is combined with Ritonavir.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Enfortumab vedotin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Enfortumab vedotin can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Procaine.]
[C01BC03, propafenone, The serum concentration of Enfortumab vedotin can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Enfortumab vedotin.]
[C01BA01, quinidine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinine.]
[C02AA02, reserpine, The serum concentration of Enfortumab vedotin can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Enfortumab vedotin can be increased when combined with Rifampicin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Enfortumab vedotin.]
[N05CM21, lemborexant, The serum concentration of Enfortumab vedotin can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Enfortumab vedotin can be increased when it is combined with Tazemetostat.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Enfortumab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi.]
